GlassScriptPhysician profile
Helen Wu
NPI 1982669586
$52,657.11
in general payments reported to CMS, 2019-2025
29 companies · $8,450 in 2025
The $8,450 reported for 2025 was more than what 98% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15K · 2020: $3,620 · 2021: $13K · 2022: $9,928 · 2023: $1,407 · 2024: $1,414 · 2025: $8,450.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,161 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $4,080 · Travel and Lodging: $1,889 · Education: $140.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,161.38 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $4,080.00 |
| Travel and Lodging | $1,889.33 |
| Education | $140.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dompe US, INC. | $16,483.73 | 2019-2025 | Oxervate |
| Allergan, INC. | $12,245.05 | 2019-2022 | |
| Bausch & Lomb Americas INC. | $6,637.66 | 2023-2025 | Xiidra, Miebo, Vyzulta |
| Shire North American Group INC | $4,346.68 | 2019 | |
| Abbvie INC. | $3,662.95 | 2022-2025 | |
| Kala Pharmaceuticals, INC. | $3,011.89 | 2019-2022 | |
| Glaukos Corporation | $1,150.24 | 2020-2025 | Kxl1b-Ce-Marked Kxlsystem, Istent Trabecular Micro-Bypass Stent System, Kxl System (Not Refurbished) |
| Tarsus Pharmaceuticals, INC. | $1,123.82 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $1,069.23 | 2019-2025 | Cequa |
| Alcon Vision LLC | $778.77 | 2019-2025 | Rocklatan, Eysuvis, Tryptyr |
| Novartis Pharmaceuticals Corporation | $355.09 | 2020-2023 | |
| Thea Pharma INC. | $354.21 | 2023 | |
| Oyster Point Pharma, INC. | $241.00 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Beaver-Visitec International, INC. | $205.94 | 2023-2025 | |
| Mallinckrodt Hospital Products INC. | $139.70 | 2025 | Acthar |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $133.75 | 2021-2024 | Tecnis Iol |
| Carl Zeiss Meditec, INC. | $129.73 | 2021 | |
| Ocular Therapeutix, INC. | $88.50 | 2020 | |
| Carl Zeiss Meditec USA, INC. | $79.08 | 2021-2025 | |
| Biotissue Holdings INC. | $77.90 | 2022-2025 | |
| Harrow Eye, LLC | $60.11 | 2025 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $55.40 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.80 | 2024 | Eylea Hd |
| Amgen INC. | $44.05 | 2024-2025 | Tepezza |
| Sandoz INC. | $36.48 | 2024 | Cimerli |
| Coherus Oncology, INC. | $35.16 | 2024 | |
| Sight Sciences, INC. | $31.74 | 2021 | |
| Abbott Laboratories | $22.35 | 2025 | Cardiomems |
| Horizon Therapeutics Plc | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Helen Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.